Filtering by:
ImmunotherapyTop Story
February 20, 2018
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
Read More
December 26, 2017
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
December 15, 2017
Year in Review: Cancer Research Insights from 2017
Read highlights about American Cancer Society research from 2017.
October 19, 2017
FDA Approves Yescarta (Axicabtagene Ciloleucel) for Adults with Certain Lymphomas
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell lymphoma.